RxDoctor Payments Data

Christon Grant

Rheumatology · Bristol, CTNPI 1750811949

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,677, more than ten times the $14 reported in 2021.

$4,761in general payments, 2019–2025

Across 214 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$748
  • Amgen$627
  • AstraZeneca$293
  • Mallinckrodt Hospital Products Inc.$277
  • UCB, Inc.$272
  • Novartis$271
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,67298%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,761 in reported general payments places this provider in the 70th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$13,045
Medicare patients
60
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept41$292,856
Humira(Cf) PenAdalimumab17$133,716
Cosentyx Unoready PenSecukinumab13$97,439
Orencia ClickjectAbatacept17$89,978
ActemraTocilizumab15$58,722
Colchicine56$2,468
Prednisone334$1,400
Sulfasalazine DrSulfasalazine37$1,275
MethotrexateMethotrexate Sodium99$1,150
Allopurinol129$1,023
Hydroxychloroquine Sulfate59$935
Alendronate Sodium97$280
Gabapentin37$256
Cyclobenzaprine Hcl11$68

Paid to pharmacies, not to this prescriber.

Other rheumatology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →